The EBMT activity survey: 1990-2010 - PubMed (original) (raw)
Multicenter Study
doi: 10.1038/bmt.2012.66. Epub 2012 Apr 30.
H Baldomero, A Gratwohl, M Bregni, S Cesaro, P Dreger, T de Witte, D Farge-Bancel, B Gaspar, J Marsh, M Mohty, C Peters, A Tichelli, A Velardi, C Ruiz de Elvira, F Falkenburg, A Sureda, A Madrigal; European Group for Blood and Marrow Transplantation (EBMT)
Affiliations
- PMID: 22543746
- DOI: 10.1038/bmt.2012.66
Multicenter Study
The EBMT activity survey: 1990-2010
J R Passweg et al. Bone Marrow Transplant. 2012 Jul.
Abstract
A total of 654 centers from 48 countries were contacted for the 2010 survey. In all, 634 centers reported a total of 33 362 hematopoietic SCT (HSCT) with 30 012 patients receiving their first transplant (12 276 allogeneic (41%) and 17 736 autologous (59%)). Main indications were leukemias: 9355 (31%; 93% allogeneic), lymphoid neoplasias specifically Non Hodgkin's lymphoma, Hodgkin's lymphoma and plasma cell disorders: 17 362 (58%; 12% allogeneic), solid tumors: 1585 (5%; 6% allogeneic) and non-malignant disorders: 1609 (6%; 88% allogeneic). There were more unrelated donors than HLA-identical sibling donors (53% versus 41%); the proportion of peripheral blood as stem cell source was 99% for autologous and 71% for allogeneic HSCT. Cord blood was primarily used in allogeneic transplants (6% of total) with three autologous cord blood HSCT being reported. The number of transplants has increased by 19% since 2005 (allogeneic 37% and autologous 9%) and continued to increase by about 1100 HSCT per year since 2000. Patterns of increase were distinct and different. The data show the development of transplantation in Europe since 1990, with the number of patients receiving a HSCT increasing from 4200 to over 30 000 annually. The most impressive trend seen is the steady increase of unrelated donor transplantation, in parallel to the availability of unrelated donors through donor registries.
Similar articles
- The EBMT activity survey 2009: trends over the past 5 years.
Baldomero H, Gratwohl M, Gratwohl A, Tichelli A, Niederwieser D, Madrigal A, Frauendorfer K; European Group for Blood and Marrow Transplantation EBMT. Baldomero H, et al. Bone Marrow Transplant. 2011 Apr;46(4):485-501. doi: 10.1038/bmt.2011.11. Epub 2011 Feb 28. Bone Marrow Transplant. 2011. PMID: 21358689 - Increasing use of reduced intensity conditioning transplants: report of the 2001 EBMT activity survey.
Gratwohl A, Baldomero H, Passweg J, Urbano-Ispizua A; European Group for Blood and Marrow Transplantation (EBMT). Accreditation Committee. Gratwohl A, et al. Bone Marrow Transplant. 2002 Dec;30(12):813-31. doi: 10.1038/sj.bmt.1703819. Bone Marrow Transplant. 2002. PMID: 12476273 - Bone marrow transplantation activity in Europe 1992: report from the European Group for Bone Marrow Transplantation (EBMT).
Gratwohl A, Hermans J. Gratwohl A, et al. Bone Marrow Transplant. 1994 Jan;13(1):5-10. Bone Marrow Transplant. 1994. PMID: 8019452 - The activity of hematopoietic stem cell transplantation in Korea.
Lee JW, Kim CC. Lee JW, et al. Bone Marrow Transplant. 2008 Aug;42 Suppl 1:S92-S95. doi: 10.1038/bmt.2008.127. Bone Marrow Transplant. 2008. PMID: 18724315 Review.
Cited by
- Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies undergoing intensive chemotherapy or stem cell transplantation.
Desborough M, Estcourt LJ, Doree C, Trivella M, Hopewell S, Stanworth SJ, Murphy MF. Desborough M, et al. Cochrane Database Syst Rev. 2016 Aug 22;2016(8):CD010982. doi: 10.1002/14651858.CD010982.pub2. Cochrane Database Syst Rev. 2016. PMID: 27548292 Free PMC article. Review. - Impact of drug development on the use of stem cell transplantation: a report by the European Society for Blood and Marrow Transplantation (EBMT).
Passweg JR, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P, Duarte RF, Dufour C, Kuball J, Farge-Bancel D, Gennery A, Kröger N, Lanza F, Nagler A, Sureda A, Mohty M. Passweg JR, et al. Bone Marrow Transplant. 2017 Feb;52(2):191-196. doi: 10.1038/bmt.2016.258. Epub 2016 Nov 7. Bone Marrow Transplant. 2017. PMID: 27819687 - Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation.
Crucitti L, Crocchiolo R, Toffalori C, Mazzi B, Greco R, Signori A, Sizzano F, Chiesa L, Zino E, Lupo Stanghellini MT, Assanelli A, Carrabba MG, Marktel S, Marcatti M, Bordignon C, Corti C, Bernardi M, Peccatori J, Bonini C, Fleischhauer K, Ciceri F, Vago L. Crucitti L, et al. Leukemia. 2015 May;29(5):1143-52. doi: 10.1038/leu.2014.314. Epub 2014 Nov 5. Leukemia. 2015. PMID: 25371177 - A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation.
Estcourt LJ, Crighton GL, Wood EM, Stanworth S, Trivella M, Doree C, Tinmouth A, Murphy MF. Estcourt LJ, et al. Cochrane Database Syst Rev. 2014;(3):CD010981. doi: 10.1002/14651858.CD010981. Cochrane Database Syst Rev. 2014. PMID: 25722649 Free PMC article. Updated. - Poor graft function can be durably and safely improved by CD34+-selected stem cell boosts after allogeneic unrelated matched or mismatched hematopoietic cell transplantation.
Haen SP, Schumm M, Faul C, Kanz L, Bethge WA, Vogel W. Haen SP, et al. J Cancer Res Clin Oncol. 2015 Dec;141(12):2241-51. doi: 10.1007/s00432-015-2027-x. Epub 2015 Aug 14. J Cancer Res Clin Oncol. 2015. PMID: 26272482
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials